Similar high-throughput methods using the In-Cell Western (ICW) technology were previously successfully developed to quantify dystrophin to evaluate exon skipping efficiency after antisense oligonucleotide treatment in Duchenne Muscular Dystrophy (DMD) patients’ myotubes [52,53]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.